Dexcom (DXCM) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$1,575.13

▲(3.02% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $1,575.13 with a high forecast of $1,773.89 and a low forecast of $1,385.32. The average price target represents a 3.02% change from the last price of $1,529.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1130":"$1,130","1291":"$1,291","1452":"$1,452","1613":"$1,613","1774":"$1,774"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1773.88836345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.77K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1575.1333647441177,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.58K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1385.32234098,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.39K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1130,1291,1452,1613,1774],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1529,1547.8375664192308,1566.6751328384616,1585.5126992576922,1604.350265676923,1623.187832096154,1642.0253985153847,1660.8629649346153,1679.7005313538461,1698.538097773077,1717.3756641923078,1736.2132306115384,1755.0507970307692,{"y":1773.88836345,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1529,1532.548720364932,1536.0974407298643,1539.6461610947963,1543.1948814597285,1546.7436018246606,1550.2923221895928,1553.8410425545248,1557.389762919457,1560.9384832843891,1564.4872036493214,1568.0359240142534,1571.5846443791856,{"y":1575.1333647441177,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1529,1517.9478723830769,1506.895744766154,1495.8436171492308,1484.7914895323077,1473.7393619153847,1462.6872342984616,1451.6351066815384,1440.5829790646153,1429.5308514476924,1418.4787238307692,1407.426596213846,1396.3744685969232,{"y":1385.32234098,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1428.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1234.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1131.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1169,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1213,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1310,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1243,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1209.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1209.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1241.72,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1241.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1430,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1529,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,774

Average Price Target$1,575

Lowest Price Target$1,385

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

$1,520.48

Buy

-0.56%

Downside

Reiterated

09/09/26

Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)

Joanne Wuensch

Citi

$1,486.69→$1,773.89

Buy

16.02%

Upside

Reiterated

08/14/26

Citi Reaffirms Their Buy Rating on Dexcom (DXCM)

Anthony Petrone

Mizuho Securities

$1,604.95

Buy

4.97%

Upside

Reiterated

08/04/26

Mizuho Securities Sticks to Its Buy Rating for Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

$1,385.32

Hold

-9.40%

Downside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Neuren Pharmaceuticals Limited (Other OTC: NURPF), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

William Plovanic

Canaccord Genuity

$1,385.32→$1,520.48

Buy

-0.56%

Downside

Reiterated

08/03/26

DexCom price target raised to $90 from $82 at CanaccordDexCom price target raised to $90 from $82 at Canaccord

Steven Silver

Argus Research

$1,452.9→$1,621.84

Buy

6.07%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Dexcom (DXCM), AxoGen (AXGN)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Analyst Reiterates Buy on Dexcom, Citing Strong Q2 Growth, Expanding G7 Adoption and CMS Coverage Upside

Jayson Bedford

Raymond James

$1,537.37→$1,588.05

Buy

3.86%

Upside

Reiterated

07/31/26

DexCom price target raised to $94 from $91 at Raymond JamesDexCom price target raised to $94 from $91 at Raymond James

Jeff Johnson

Robert W. Baird

$1,351.53→$1,773.89

Buy

16.02%

Upside

Reiterated

07/31/26

DexCom price target raised to $105 from $80 at BairdDexCom price target raised to $105 from $80 at Baird

Richard Newitter

Truist Financial

$1,469.79→$1,571.16

Buy

2.76%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Merit Medical Systems (MMSI), Dexcom (DXCM)

Jonathan Block

Stifel Nicolaus

$1,520.48→$1,604.95

Buy

4.97%

Upside

Assigned

07/31/26

DexCom price target raised to $95 from $90 at StifelDexCom price target raised to $95 from $90 at Stifel

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: AptarGroup (NYSE: ATR), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

Kieran Ryan

Deutsche Bank

Not Ranked

Deutsche Bank

$1,452.9→$1,554.26

Buy

1.65%

Upside

Assigned

07/31/26

DexCom price target raised to $92 from $86 at Deutsche BankDexCom price target raised to $92 from $86 at Deutsche Bank

Kendall Au

RBC Capital

$1,436→$1,520.48

Buy

-0.56%

Downside

Reiterated

07/31/26

RBC Capital Remains a Buy on Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$1,486.69→$1,604.95

Buy

4.97%

Upside

Reiterated

07/31/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

$1,520.48

Buy

-0.56%

Downside

Reiterated

09/09/26

Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)

Joanne Wuensch

Citi

$1,486.69→$1,773.89

Buy

16.02%

Upside

Reiterated

08/14/26

Citi Reaffirms Their Buy Rating on Dexcom (DXCM)

Anthony Petrone

Mizuho Securities

$1,604.95

Buy

4.97%

Upside

Reiterated

08/04/26

Mizuho Securities Sticks to Its Buy Rating for Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

$1,385.32

Hold

-9.40%

Downside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Neuren Pharmaceuticals Limited (Other OTC: NURPF), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

William Plovanic

Canaccord Genuity

$1,385.32→$1,520.48

Buy

-0.56%

Downside

Reiterated

08/03/26

DexCom price target raised to $90 from $82 at CanaccordDexCom price target raised to $90 from $82 at Canaccord

Steven Silver

Argus Research

$1,452.9→$1,621.84

Buy

6.07%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Dexcom (DXCM), AxoGen (AXGN)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Analyst Reiterates Buy on Dexcom, Citing Strong Q2 Growth, Expanding G7 Adoption and CMS Coverage Upside

Jayson Bedford

Raymond James

$1,537.37→$1,588.05

Buy

3.86%

Upside

Reiterated

07/31/26

DexCom price target raised to $94 from $91 at Raymond JamesDexCom price target raised to $94 from $91 at Raymond James

Jeff Johnson

Robert W. Baird

$1,351.53→$1,773.89

Buy

16.02%

Upside

Reiterated

07/31/26

DexCom price target raised to $105 from $80 at BairdDexCom price target raised to $105 from $80 at Baird

Richard Newitter

Truist Financial

$1,469.79→$1,571.16

Buy

2.76%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Merit Medical Systems (MMSI), Dexcom (DXCM)

Jonathan Block

Stifel Nicolaus

$1,520.48→$1,604.95

Buy

4.97%

Upside

Assigned

07/31/26

DexCom price target raised to $95 from $90 at StifelDexCom price target raised to $95 from $90 at Stifel

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: AptarGroup (NYSE: ATR), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

Kieran Ryan

Deutsche Bank

Not Ranked

Deutsche Bank

$1,452.9→$1,554.26

Buy

1.65%

Upside

Assigned

07/31/26

DexCom price target raised to $92 from $86 at Deutsche BankDexCom price target raised to $92 from $86 at Deutsche Bank

Kendall Au

RBC Capital

$1,436→$1,520.48

Buy

-0.56%

Downside

Reiterated

07/31/26

RBC Capital Remains a Buy on Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$1,486.69→$1,604.95

Buy

4.97%

Upside

Reiterated

07/31/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

STOKStoke Therapeutics

AXGNAxoGen

JAZZJazz Pharmaceuticals

PTGXProtagonist Therapeutics

CABACabaletta Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months

Mike KratkyLeerink Partners

Success Rate

12/18 ratings generated profit

Average Return

+3.93%

Copying Mike Kratky's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.93% per trade.

1 Year

Steven LichtmanWilliam Blair

Success Rate

36/50 ratings generated profit

Average Return

+36.05%

Copying Steven Lichtman's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +36.05% per trade.

2 Years

Steven LichtmanWilliam Blair

Success Rate

39/50 ratings generated profit

Average Return

+83.71%

Copying Steven Lichtman's trades and holding each position for 2 Years would result in 78.00% of your transactions generating a profit, with an average return of +83.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DXCM average Analyst price target in the past 3 months is 1,575.13.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $11.34 with a range of $10.47 to $11.83. The previous quarter’s EPS was $11.83. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $22.44B with a range of $22.11B to $22.70B. The previous quarter’s sales results were $22.10B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is MX:DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 1,575.13.

What is MX:DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 3.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Dexcom a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is Dexcom’s share price target?

The average share price target for Dexcom is 1,575.13. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $1,773.89 ,and the lowest forecast is $1,385.32. The average share price target represents 3.02% Increase from the current price of $1,529.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Dexcom?

To buy shares of MX:DXCM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Detailed List of Analyst Forecasts